These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31183929)

  • 1. Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS).
    Melmer A; Züger T; Lewis DM; Leibrand S; Stettler C; Laimer M
    Diabetes Obes Metab; 2019 Oct; 21(10):2333-2337. PubMed ID: 31183929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
    Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between HbA
    Seyed Ahmadi S; Westman K; Pivodic A; Ólafsdóttir AF; Dahlqvist S; Hirsch IB; Hellman J; Ekelund M; Heise T; Polonsky W; Wijkman M; Schwarcz E; Lind M
    Diabetes Care; 2020 Sep; 43(9):2017-2024. PubMed ID: 32641374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.
    Renard E; Farret A; Kropff J; Bruttomesso D; Messori M; Place J; Visentin R; Calore R; Toffanin C; Di Palma F; Lanzola G; Magni P; Boscari F; Galasso S; Avogaro A; Keith-Hynes P; Kovatchev B; Del Favero S; Cobelli C; Magni L; DeVries JH;
    Diabetes Care; 2016 Jul; 39(7):1151-60. PubMed ID: 27208331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes with different technology modalities in type 1 diabetes.
    Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1845-1850. PubMed ID: 33838993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twitter Analysis of #OpenAPS DIY Artificial Pancreas Technology Use Suggests Improved A1C and Quality of Life.
    Litchman ML; Lewis D; Kelly LA; Gee PM
    J Diabetes Sci Technol; 2019 Mar; 13(2):164-170. PubMed ID: 30198751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial.
    O'Connell MA; Donath S; O'Neal DN; Colman PG; Ambler GR; Jones TW; Davis EA; Cameron FJ
    Diabetologia; 2009 Jul; 52(7):1250-7. PubMed ID: 19396424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range.
    Sivasubramaniyam S; Amiel SA; Choudhary P
    Diabet Med; 2017 Oct; 34(10):1456-1460. PubMed ID: 28763121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel continuous glucose monitoring guided system for adjustment of insulin dosing - PumpTune: a randomized controlled trial.
    Anderson D; Phelan H; Jones K; Smart C; Oldmeadow C; King B; Crock P
    Pediatr Diabetes; 2016 Nov; 17(7):478-482. PubMed ID: 26701831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting the Relationships Between Measures of Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring Data Sets.
    Gimenez M; Tannen AJ; Reddy M; Moscardo V; Conget I; Oliver N
    Diabetes Care; 2018 Feb; 41(2):326-332. PubMed ID: 29191845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial.
    Heimbürger SMN; Hoe B; Nielsen CN; Bergmann NC; Hartmann B; Holst JJ; Vilsbøll T; Dejgaard TF; Christensen MB; Knop FK
    Diabetologia; 2021 Nov; 64(11):2425-2431. PubMed ID: 34405256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.
    Haidar A; Legault L; Matteau-Pelletier L; Messier V; Dallaire M; Ladouceur M; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):595-604. PubMed ID: 26066705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes.
    Del Favero S; Place J; Kropff J; Messori M; Keith-Hynes P; Visentin R; Monaro M; Galasso S; Boscari F; Toffanin C; Di Palma F; Lanzola G; Scarpellini S; Farret A; Kovatchev B; Avogaro A; Bruttomesso D; Magni L; DeVries JH; Cobelli C; Renard E;
    Diabetes Obes Metab; 2015 May; 17(5):468-76. PubMed ID: 25600304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.